OGDEN MANUFACTURING PLANT OPTIFLUX 160NRE DIALYZER FINISHED ASSY. DIALYZER, HIGH PERMEABILITY WITH OR WITHOUT SEALED DIALYSATE SYSTEM
|
Back to Search Results |
|
Model Number 0500316E |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Itching Sensation (1943); Swelling (2091); Dizziness (2194); Reaction (2414); Diaphoresis (2452); Chest Tightness/Pressure (2463)
|
Event Date 05/19/2020 |
Event Type
Injury
|
Manufacturer Narrative
|
Clinical review: based on the available information, there is a temporal and a likely causal relationship between the fresenius optiflux 160nre dialyzer and the patient¿s reaction (characterized by dizziness, chest tightness, itching, with face and neck red, ears and tongue swollen, difficulty speaking, and sweating during the hd treatment).
Although rare, hypersensitivity or anaphylactoid reactions to optiflux dialyzers are a known risk during hemodialysis.
There is no evidence of an optiflux 160nre dialyzer product deficiency or malfunction.
Additionally, although the patient experienced an adverse reaction during treatment, there is no allegation of a product malfunction or deficiency related to this event.
The plant investigation is in process.
A supplemental mdr will be submitted upon completion of this activity.
.
|
|
Event Description
|
A voluntary medwatch report was received from a hemodialysis (hd) clinic manager reporting a patient adverse event.
A hemodialysis (hd) patient arrived for a regularly scheduled treatment on (b)(6) 2020.
This patient received dialysis three times per week with a three hour and thirty-minute treatment.
The patient¿s pre-vital signs were as follows: blood pressure (bp)147/76, pulse 79, temperature 96.
8.
At approximately 0925 hours dialysis was initiated via an arteriovenous fistula (avf) (location not provided) utilizing the optiflux 160nre dialyzer which the patient had been using without incident since hd initiation.
Within approximately 5-10 minutes into the treatment the patient complained of feeling dizzy, chest tightness and itching, as well as displaying a red face and neck, and swollen ears and tongue.
In addition, the patient had difficulty speaking and was sweating.
Vital signs were recorded at the time as bp 109/67 and pulse 121.
Treatment was terminated at this time and the patient was administered oxygen via nasal cannula at 3l/min.
The patient was also administered 400ml of normal saline (ns).
At 0935 hours 911 was called and 25mg oral benadryl was administered.
Emergency medical services (ems) arrived and in route to the emergency room (er) the patient was given an intramuscular (im) injection of 0.
3mg epinephrine (epi).
Once at the er, the patient received 50mg intravenous (iv) benadryl, 0.
3mg im epi, 20mg iv famotidine and 25mg iv solumedrol.
The patient was admitted to the intensive care unit (icu) for close monitoring with orders for iv benadryl as needed and scheduled famotidine twice a day (dose not provided).
The patient recovered and was discharged from the hospital on (b)(6) 2020 and returned to hd therapy on (b)(6) 2020.
The optiflux 160nre was marked as an allergy and the patient was switched to the nipro cellentia 17h dialyzer.
|
|
Search Alerts/Recalls
|
|
|